Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06086522 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Qualigen Theraputics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 4
- Study locations
NCT06086522 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Qualigen Theraputics. The registered enrollment target is 54 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (76% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06086522, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Qualigen Theraputics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 4
- Study locations
Study Summary
Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patient.
Conditions Studied
Interventions
- DRUG QN-302
Study Locations (4)
Arizona
- HonorHealth - Scottsdale
Connecticut
- Yale - New Haven
Michigan
- START Midwest - Grand Rapids
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06086522
The ClinicalTrials.gov registry entry for NCT06086522 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (76% lower). The listed sponsor is Qualigen Theraputics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which QN-302 is the first listed.
NCT06086522 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Connecticut, Michigan.
Frequently Asked Questions
What is clinical trial NCT06086522 about?
NCT06086522 is a clinical study titled "Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors". Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intrav...
What is the current status of trial NCT06086522?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2023-11-01. Estimated completion is 2026-12.
What conditions does trial NCT06086522 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06086522?
The interventions under investigation include: QN-302 (DRUG).
Who is sponsoring clinical trial NCT06086522?
This trial is sponsored by Qualigen Theraputics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06086522 being conducted?
This trial has 4 study locations across Arizona, Connecticut, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.